… In total, the analysis included 480 patients—292 in the modafinil group and 188 in the
placebo group (safety analysis set). FOSQ efficacy data were available for 442 patients: 263 for …

… of modafinil, a recently synthesized wake-promoting drug, on healthy individuals. Modafinil
… It may be favorable only in circumstances of excessive fatigue or pressure not manageable …

… efficacy and safety profile in narcolepsy [18]. In the United States, modafinil and armodafinil
… Although modafinil and armodafinil clearly have efficacy, there are some patients in whom …

… modafinil and armodafinil significantly improved subjective and objective daytime sleepiness…
Regarding safety profiles and AEs, both modafinil and armodafinil were well-tolerated by …

… Modafinil is a non-amphetamine stimulant the Food and Drug Administration (FDA) approved
in 1998 to improve excessive sleepiness … Neither efficacy nor safety has been established …

… modafinil to include improving wakefulness in patients with excessive sleepiness associated
with shift work sleep … More information on modafinil’s safety profile is provided in the product …

… sleep apnea syndrome (OSAS). Narcolepsy and idiopathic hypersomnia (IH) induce severe
excessive daytime sleepiness but … Patients from this group can therefore be defined as safe …

… Our findings suggest that excessive daytime sleepiness can be improved by pitolisant for at
… and safety findings to these populations. Furthermore, patients who had previously received …

… modafinil augmentation in major depressive disorder (MDD) patients with fatigue and excessive
sleepiness … The safety/tolerability data from this study suggest that modafinil treatment is …

… the long-term effects and safety profile of modafinil in children. One small study (… modafinil
in the treatment of excessive daytime sleepiness (EDS) in children. This study found modafinil …